Compare Krispy Kreme Inc (DNUT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs Merck & Co., Inc. — how do they compare? Krispy Kreme Inc trades at $2.95 (market cap $521.37M), while Merck & Co., Inc. trades at $146.49 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 673.8× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays the higher dividend (3.47%). Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 45 Days and Merck & Co., Inc. for 98 Days on average.
| DNUT | MRK | |
|---|---|---|
Market Cap | $521.37M | $351.28B |
Volume | 2,293,015 | 7,969,665 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $156.43 |
52-Week Low | $2.87 | $82.49 |
Typical Hold Time | 45 Days | 98 Days |
Enterprise Value | $1.76B | $398.04B |
Dividend Yield | 3.47% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $2.945, up 0.86% with a bullish technical signal despite mixed earnings. The company shows strong gross margins (75.19%) but negative net income (-$515.77M for 2025) and declining revenue trends. Analyst sentiment is positive with 50% buy ratings, though recent news highlights ongoing legal investigations into fiduciary duties.
Investment outlook remains cautious due to profitability challenges and legal overhangs, offset by low valuation multiples (P/S 0.35) and product innovation. Key risks include sustained losses, debt burden, and litigation outcomes. Upside depends on margin improvement and successful new launches.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
